Natera (NASDAQ:NTRA) Price Target Lowered to $55.00 at Credit Suisse Group

Natera (NASDAQ:NTRAGet Rating) had its price objective decreased by equities researchers at Credit Suisse Group from $70.00 to $55.00 in a research report issued to clients and investors on Monday, The Fly reports. The firm currently has an “outperform” rating on the medical research company’s stock. Credit Suisse Group’s price objective would indicate a potential upside of 60.96% from the stock’s current price.

Several other research firms have also weighed in on NTRA. Robert W. Baird reduced their target price on Natera from $72.00 to $65.00 in a report on Wednesday, November 9th. StockNews.com assumed coverage on Natera in a report on Wednesday, October 12th. They set a “sell” rating on the stock. Piper Sandler lifted their target price on Natera from $60.00 to $70.00 and gave the stock an “overweight” rating in a report on Wednesday, August 17th. JPMorgan Chase & Co. lifted their target price on Natera from $80.00 to $100.00 in a report on Friday, August 5th. Finally, BTIG Research cut their price target on Natera from $95.00 to $75.00 in a report on Wednesday, November 9th. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. According to MarketBeat, Natera has an average rating of “Moderate Buy” and a consensus target price of $82.64.

Natera Stock Performance

NTRA stock opened at $34.17 on Monday. The business’s 50-day moving average price is $44.85 and its two-hundred day moving average price is $42.88. The company has a current ratio of 3.10, a quick ratio of 2.95 and a debt-to-equity ratio of 0.78. The firm has a market cap of $3.34 billion, a PE ratio of -6.02 and a beta of 1.33. Natera has a 1-year low of $26.10 and a 1-year high of $118.00.

Insider Activity

In related news, insider Daniel Rabinowitz sold 729 shares of the company’s stock in a transaction dated Wednesday, September 28th. The stock was sold at an average price of $44.04, for a total transaction of $32,105.16. Following the sale, the insider now owns 145,827 shares in the company, valued at $6,422,221.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, insider Daniel Rabinowitz sold 729 shares of the company’s stock in a transaction dated Wednesday, September 28th. The stock was sold at an average price of $44.04, for a total transaction of $32,105.16. Following the sale, the insider now owns 145,827 shares in the company, valued at $6,422,221.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Michael Burkes Brophy sold 2,488 shares of the company’s stock in a transaction dated Monday, October 24th. The stock was sold at an average price of $42.41, for a total value of $105,516.08. Following the sale, the chief financial officer now owns 89,326 shares in the company, valued at approximately $3,788,315.66. The disclosure for this sale can be found here. Insiders have sold a total of 18,359 shares of company stock worth $797,832 over the last three months. Corporate insiders own 10.27% of the company’s stock.

Institutional Trading of Natera

Institutional investors and hedge funds have recently bought and sold shares of the stock. CWM LLC increased its position in Natera by 1,041.0% during the first quarter. CWM LLC now owns 696 shares of the medical research company’s stock worth $28,000 after buying an additional 635 shares during the last quarter. SG Americas Securities LLC increased its position in Natera by 486.2% during the first quarter. SG Americas Securities LLC now owns 30,422 shares of the medical research company’s stock worth $1,238,000 after buying an additional 25,232 shares during the last quarter. AlphaMark Advisors LLC increased its position in Natera by 66.7% during the first quarter. AlphaMark Advisors LLC now owns 750 shares of the medical research company’s stock worth $31,000 after buying an additional 300 shares during the last quarter. Granite Investment Partners LLC increased its position in Natera by 56.7% during the first quarter. Granite Investment Partners LLC now owns 73,738 shares of the medical research company’s stock worth $3,000,000 after buying an additional 26,685 shares during the last quarter. Finally, State of New Jersey Common Pension Fund D increased its position in Natera by 8.1% during the first quarter. State of New Jersey Common Pension Fund D now owns 54,323 shares of the medical research company’s stock worth $2,210,000 after buying an additional 4,076 shares during the last quarter. Institutional investors own 92.95% of the company’s stock.

Natera Company Profile

(Get Rating)

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

Featured Articles

The Fly logo

Analyst Recommendations for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.